Tisotumab Vedotin: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01633-8
Abstract: Tisotumab vedotin (Tivdak™) is an antibody-drug conjugate comprising a fully human monoclonal antibody specific for tissue factor (TF-011) conjugated to monomethyl auristatin E (MMAE) that has been engineered to target tissue factor expressing tumours. Based… read more here.
Keywords: tisotumab vedotin; vedotin; first approval; vedotin first ... See more keywords
Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2020.1718103
Abstract: ABSTRACT Objectives: To assess the risk of adverse events (AEs) associated with brentuximab vedotin in lymphoma patients. Methods: Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab… read more here.
Keywords: brentuximab vedotin; vedotin; risk adverse; lymphoma patients ... See more keywords
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-1768
Abstract: Purpose: In classical Hodgkin lymphoma, the malignant Reed–Sternberg cells express the cell surface marker CD30. Brentuximab vedotin is an antibody–drug conjugate (ADC) that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (MMAE), to CD30-positive… read more here.
Keywords: hodgkin lymphoma; brentuximab vedotin; vedotin; resistance ... See more keywords
A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221139775
Abstract: Objective To review and compare the pharmacology, efficacy, and safety of the novel tissue factor antibody–drug conjugate, tisotumab vedotin Data sources Literature search was performed through PubMed MEDLINE, Google Scholar, ClinicalTrials.gov, and the Food and… read more here.
Keywords: novel tissue; tissue factor; vedotin; drug ... See more keywords